Medicare GLP-1 Bridge Guide · Updated July 2026
Best GLP-1 on Medicare GLP-1 Bridge: Wegovy, Zepbound, or Foundayo?
By The RX Index Editorial Team · · Last verified:
Here's the honest answer: there's no single best GLP-1 on Medicare GLP-1 Bridge. Every eligible fill costs the same $50 -- so the best pick isn't about price. It comes down to the drug, the form, your daily routine, your other medications, and whether your prescription even belongs in the Bridge at all. In the trials (run separately, not head-to-head), Zepbound showed the most average weight loss. Wegovy gives you a shot or a pill. Foundayo is the easiest pill to take. But before any of that matters, one thing has to be true: the Bridge has to be your coverage path, and you have to qualify.
The Medicare GLP-1 Bridge is a real, temporary government program that runs July 1, 2026 through December 31, 2027. It lets eligible Medicare Part D members get three FDA-approved weight-loss drugs for a flat $50 copay per fill, no matter which one you pick or what dose you're on. According to a KFF analysis of 2023 claims data, about 3.8 million Medicare Part D enrollees met the Bridge criteria -- that's an estimate of who's eligible, not a promise of who'll enroll. The $50 is real. There are two catches most guides skip, and we'll get to them.
Is This Medicare GLP-1 Bridge Comparison for You?
This page is for you if:
- You have Medicare Part D and think you might qualify for the $50 Bridge.
- You already got approved and are choosing between the covered drugs.
- You're helping a parent or spouse compare pills, weekly shots, and what each demands.
- You want a clear, clinician-ready shortlist -- not a generic "top 5 drugs" list.
This page is not the right fit if:
- You still need to figure out whether you qualify -- start with our eligibility guide first, then come back.
- Your prescription is mainly for type 2 diabetes, sleep apnea, fatty liver disease, or heart-attack/stroke prevention -- those go through regular Part D.
- You're shopping for compounded medications. The Bridge only covers brand-name, FDA-approved drugs.
The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.
The 60-second verdict
All three cost $50 on the Bridge, so price doesn't break the tie. Your priority does. Full detail, sources, and the big caveat are further down.
| If your priority is… | Ask your doctor about… | The catch to know |
|---|---|---|
| The most weight loss on average | Zepbound (tirzepatide) | Only the KwikPen is covered -- not the single-dose pen or vials. Needles are bought separately. |
| A familiar weekly shot | Wegovy injection (semaglutide) | There's a higher 7.2 mg dose (Wegovy HD) your doctor can step up to later, but it's not a starting dose. |
| A pill with strong results | Wegovy tablet (semaglutide) | Strict morning routine: empty stomach, no more than 4 oz of water, then wait 30 minutes. |
| The simplest pill to take | Foundayo (orforglipron) | Lower average weight loss, and it needs a careful check against your other medications. |
Last verified: against current CMS program materials and FDA prescribing information. Prices, covered drugs, and program rules can change -- we recheck monthly.
The right GLP-1 provider isn't the same for everyone -- it depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred treatment path (injection or oral), and your budget. Use The RX Index's Find My GLP-1 Path tool to get a personalized provider match with source-verified pricing before you choose. Every drug in the Bridge is FDA-approved -- compounded medications are not in the program. If you look like a Bridge candidate, check the Medicare path before any cash-pay provider.
Find My GLP-1 Path →Free · No signup · Takes about a minute
First: Is the Bridge Even Your Path -- or Does Your Drug Go Through Regular Part D?
The Medicare GLP-1 Bridge is only for weight management. If your GLP-1 is prescribed for type 2 diabetes, moderate-to-severe sleep apnea, a form of fatty liver disease, or to lower heart-attack and stroke risk, it belongs in the regular Part D process instead. So the first question isn't "which drug?" It's "which door do I walk through?"
Getting excited about Zepbound and then learning your diabetes diagnosis sends you down a different path is a frustrating way to lose a week. Here's the simple rule, straight from CMS:
| What the drug is really for | Which door you use |
|---|---|
| Weight management, and no hard exclusion applies | Medicare GLP-1 Bridge -- $50, if you qualify |
| Type 2 diabetes | Regular Part D (drugs like Ozempic, Mounjaro, Rybelsus) |
| Moderate-to-severe obstructive sleep apnea (OSA) + obesity | Regular Part D (Zepbound is FDA-approved for OSA) |
| Noncirrhotic MASH with moderate-to-advanced liver scarring | Regular Part D (Wegovy is FDA-approved for MASH) |
| Reducing heart attack / stroke risk with known heart disease | Regular Part D (Wegovy is FDA-approved for this) |
Going through Part D doesn't guarantee coverage -- whether a drug is covered, and what you pay, still depends on your plan's formulary, prior-authorization rules, and cost-sharing. But when Part D does cover it, that spending counts toward your out-of-pocket cap (the Bridge doesn't -- more below). There's also a nuance on heart disease: simply having cardiovascular disease doesn't automatically lock you out of the Bridge. A prescription written to reduce major heart events goes through Part D, but if your doctor is prescribing genuinely for weight management, they can attest to that and route it through the Bridge. That's a conversation for your prescriber.
Definitions: Part D is Medicare's prescription drug coverage. MASH (metabolic dysfunction-associated steatohepatitis) is a form of fatty liver disease. OSA (obstructive sleep apnea) is a sleep-breathing condition.
Do You Actually Qualify for the Bridge?
To use the Bridge, you must have Medicare Part D, be at least 18, be using the drug for weight management alongside diet and exercise, and meet one of three body-mass-index (BMI) pathways. Your prescriber confirms all of this on a prior-authorization form. You cannot fill out that form yourself.
Most Part D coverage qualifies -- a standalone drug plan, most Medicare Advantage plans that include drug coverage, and a few others. But a handful of plan types are excluded, so confirm yours in our eligibility guide if you're unsure.
The three BMI pathways (minimums, not separate bands -- a qualifying condition can pull you in at a lower BMI):
- 1BMI of 35 or higher at the time you started a GLP-1 -- you qualify on your weight alone. No other condition needed.
- 2BMI of 30 or higher -- you qualify if you also have heart failure with preserved ejection fraction (HFpEF), chronic kidney disease (stage 3a or higher), or uncontrolled high blood pressure. (CMS defines uncontrolled as a top number above 140 or a bottom number above 90 despite taking two blood-pressure medicines.)
- 3BMI of 27 or higher -- you qualify if you also have prediabetes, symptomatic peripheral artery disease (PAD), a previous heart attack, or a previous stroke.
Not sure whether the Bridge or regular Part D is your door, or which BMI pathway you land in? Use The RX Index's Find My GLP-1 Path tool -- it's free, takes about a minute, and helps you walk into your appointment knowing exactly what to ask.
What Does the $50 Medicare GLP-1 Bridge Actually Cover?
The Bridge covers all forms of Foundayo, all forms of Wegovy (both the injection and the pill), and Zepbound's KwikPen -- for eligible weight-management use. The single-dose Zepbound pen and vials are not covered, and the program does not pay for KwikPen needles. Each approved fill is one 28- or 30-day supply for a $50 copay; there are no 90-day Bridge fills.
| Drug / form | On the Bridge? | The important detail |
|---|---|---|
| Foundayo tablets | ✓ Covered | All FDA-approved tablet doses |
| Wegovy pill (tablet) | ✓ Covered | The daily oral option |
| Wegovy injection | ✓ Covered | Weekly pen; includes the higher 7.2 mg ("Wegovy HD") escalation dose |
| Zepbound KwikPen | ✓ Covered | Needles bought separately |
| Zepbound single-dose pen | ✗ Not covered | Don't confuse this with the KwikPen |
| Zepbound vials | ✗ Not covered | Being sold cash-pay elsewhere doesn't make it Bridge-covered |
| Ozempic, Mounjaro, Rybelsus, Saxenda | ✗ Not on the Bridge | May be covered under regular Part D for other conditions |
| Compounded GLP-1s | ✗ Not covered | The Bridge covers named, FDA-approved products only |
Which Is the Best GLP-1 on Medicare GLP-1 Bridge?
There's no universal winner, because all three covered drugs cost the same $50. Zepbound showed the most average weight loss in its trial; Wegovy comes as a weekly shot, a higher-dose shot, or a daily pill; and Foundayo is the simplest pill to take. The best pick depends on your body, your routine, and your medications -- a decision to make with your prescriber, using the comparison below.
| Treatment path | Form on Bridge | Avg. weight loss | How you take it | Main real-world catch |
|---|---|---|---|---|
| Zepbound (tirzepatide) 15 mg | KwikPen only | ~21% at 72 wks SURMOUNT-1 -- highest here | Weekly shot | KwikPen only; buy needles separately; multi-dose device to learn |
| Wegovy HD (semaglutide) 7.2 mg | Weekly pen | ~18.8% at 72 wks STEP UP | Weekly shot | Escalation dose -- not a starting option |
| Wegovy injection (semaglutide) 2.4 mg | Weekly pen | ~14.9% at 68 wks STEP 1 | Weekly shot | Weekly injection and gradual dose build-up |
| Wegovy pill (semaglutide) 25 mg | Daily tablet | ~13.6% at 64 wks OASIS 4 | Daily pill | Strict morning fast: empty stomach, 4 oz water max, wait 30 min |
| Foundayo (orforglipron) 17.2 mg | Daily tablet | ~11% at 72 wks ATTAIN-1 | Daily pill | Lower average; needs a careful medication-interaction check |
Read this before you read the numbers. Those percentages come from five different trials, with different people and lengths -- not one head-to-head test. Treat the order as a rough guide, not a promise about you. Individual results vary a lot; some people lose far more than the average, some less.
One real head-to-head exists. Zepbound and the standard Wegovy injection were compared directly in SURMOUNT-5 (published in The New England Journal of Medicine, 2025). At 72 weeks, tirzepatide produced about 20.2% average weight loss versus about 13.7% for semaglutide, at the maximum tolerated doses. Between those two, tirzepatide came out ahead. That result doesn't settle how Zepbound compares to Wegovy HD, either pill, or what happens for any one person.
Zepbound (tirzepatide): the most weight loss -- with a device you have to get right
Zepbound showed the largest average weight loss of the group -- about 21% of body weight at 72 weeks in its main trial (the 15 mg dose), and it beat standard Wegovy injection head-to-head in SURMOUNT-5. On the Bridge, only the multi-dose KwikPen is covered, needles are separate, and that ~21% is the top-dose average, not a target for any one person.
The KwikPen is a multi-dose device: you use the same pen for multiple injections over the fill period, attaching a fresh needle each time. Most people adjust to this quickly, but it is a different user experience than single-dose injection pens. Ask your prescriber to walk you through it, or request a demonstration at the pharmacy the first time. Best fit: people who want the most average weight loss in the trial data and are comfortable with -- or willing to learn -- a weekly injection routine.
Wegovy HD (semaglutide, 7.2 mg): the highest-dose shot -- but not where you start
Wegovy HD showed about 18.8% average weight loss at 72 weeks in the STEP UP trial. It's covered by the Bridge as an escalation dose -- meaning your prescriber can step you up to it after you've done well on standard Wegovy injection. You cannot start here. If you're new to semaglutide, the entry point is the 2.4 mg Wegovy injection, and Wegovy HD is a conversation to have with your prescriber several months in. Best fit: current Wegovy injection users who want to discuss whether a higher dose is appropriate for them.
Wegovy injection (semaglutide, 2.4 mg): the familiar weekly shot with the longest track record
The standard Wegovy injection showed about 14.9% average weight loss at 68 weeks in STEP 1. It is the most established covered option -- semaglutide for weight management has been in use the longest, and the side-effect profile is well-understood. You start at a lower dose and work up to 2.4 mg over about 16 to 20 weeks. Best fit: people who prefer a weekly injection with a long real-world safety record and are comfortable with a gradual dose build-up.
Wegovy pill (semaglutide, 25 mg): the oral option with strong results -- and a strict routine
The Wegovy tablet showed about 13.6% average weight loss at 64 weeks in OASIS 4. No injections -- it's a daily pill. The catch is a strict morning routine: take it first thing on an empty stomach, with no more than 4 oz (about half a small cup) of water, then wait at least 30 minutes before eating, drinking anything else, or taking other medications. Missing steps or taking it with more water lowers absorption. If your morning schedule is consistent, this works well; if your days are unpredictable, the routine is harder to maintain than people expect. Best fit: needle-averse patients with a predictable morning routine who want an oral semaglutide option.
Foundayo (orforglipron, 17.2 mg): the simplest pill to take -- with the lowest average weight loss
Foundayo showed about 11% average weight loss at 72 weeks in ATTAIN-1. It's a daily tablet you can take at any time, with or without food -- no fasting window, no water restriction. That makes it the easiest covered pill to fit into most routines.
Two things to know before choosing it. First, the average weight loss is lower than the other covered options. Second, orforglipron is metabolized through the CYP3A4 enzyme pathway, which means it has meaningful interactions with a number of common medications -- your prescriber will need to review your full medication list before prescribing. Foundayo was FDA-approved in June 2025, so its long-term real-world data is still accumulating compared to the semaglutide and tirzepatide drugs. Best fit: people who want the simplest oral dosing routine, whose medication list is compatible, and who are comfortable with a lower average weight-loss ceiling on trial data.
The Two Catches Most Guides Skip
The Bridge is genuinely valuable -- $50 for FDA-approved GLP-1s is a real deal. But two facts about how it works get quietly skipped by most articles.
Catch 1: The $50 does not count toward your Part D out-of-pocket maximum.
Regular Part D spending counts toward your deductible and your $2,100 (2026) yearly out-of-pocket cap. Bridge spending does not. That means if you hit the cap on other Part D drugs, your Bridge copay stays at $50 regardless -- it won't be zeroed out by catastrophic coverage. It also means Extra Help (the federal low-income subsidy) and manufacturer coupons cannot lower the $50. What you see is what you pay, every fill, all year.
Catch 2: If Part D already paid for a GLP-1 for you in 2026, you're excluded from the Bridge.
CMS checks its own claims data. If your Part D plan paid for Ozempic, Mounjaro, Wegovy, Zepbound, Foundayo, Saxenda, Victoza, Trulicity, or Rybelsus at any point during 2026, you are not eligible for the Bridge in 2026. This isn't a minor technicality -- it's the design of the program. Combined with the diagnosis rules (diabetes, OSA, MASH, and cardiovascular indication all route to regular Part D), the Bridge is built for people who couldn't already access a GLP-1 through their plan.
How to Get Your First Bridge Fill
The Bridge is pharmacy-triggered -- the process starts at the pharmacy, not your doctor's office. Here's how it flows once you've chosen a drug with your prescriber:
- 1Confirm you're a Bridge candidate. Go through the BMI pathway check and diagnosis rules above. Your prescriber has the official CMS prior-authorization form; they confirm eligibility on it, not you.
- 2Have your prescriber write the prescription and direct the pharmacy to the Bridge billing route. The pharmacy submits the claim through the Bridge (BIN 028918, PCN MEDDGLP1BR). You don't need a Part D denial first.
- 3Check the prior authorization. Your prescriber submits it -- you can't. The request usually reaches the prescriber within 24 to 72 hours after the pharmacy sends the claim; once a complete authorization is submitted, the decision is mailed to you and your doctor within 72 hours. There's no formal appeal, but corrected or additional information can be resubmitted.
- 4Use the right phone number. Prescribers can call the Bridge Call Center at 855-273-0102 (Mon-Fri, 8 a.m.-7 p.m. ET). Pharmacies can reach the help desk at 844-673-0910. As a patient, call 1-800-MEDICARE (1-800-633-4227) for general help.
Good news on refills: once your first fill is approved, you don't need a new prior authorization for refills or dose changes on the same drug -- only if you switch to a different covered drug. For the full walkthrough, see our Medicare Bridge prior-authorization guide.
What Happens After December 31, 2027?
The Bridge is scheduled to end on December 31, 2027. Its intended successor, the BALANCE model, wasn't launched in Part D for 2027, so as of now there's no guaranteed way to keep $50 weight-loss coverage after that date. Watch CMS for updates rather than counting on any specific program.
This is a short-term demonstration. CMS is collecting usage data to inform whatever comes next, and any continuation would take new federal action that hasn't been announced. If you start now, talk with your prescriber about what your plan looks like if the program isn't extended -- including whether your situation might qualify for regular Part D coverage down the road.
What Are My Options If I Don't Qualify for the Medicare GLP-1 Bridge?
If you don't have Part D, don't meet a BMI pathway, or want a drug or form the Bridge doesn't cover, your realistic options are: enroll in an eligible Part D plan at a valid enrollment period (then confirm you meet every other Bridge requirement), or pay cash for an FDA-approved GLP-1.
For that reader: telehealth platforms like Ro connect you with licensed providers who can prescribe FDA-approved weight-management medications -- including Zepbound and the pill Foundayo -- when it's appropriate for you. Two things to know plainly. First, Ro doesn't bill Medicare, Medicare Supplement (Medigap), or TRICARE -- but people with those plans can still use it as a cash-pay option. Second, the cost is real: Ro Body is $39 for the first month, then $149/month (as low as $74/month if you prepay for a year), with the medication billed on top (verified July 18, 2026). That's a lot more than $50 -- but it's the same FDA-approved medications, without the Bridge's specific BMI-and-condition rules (a provider still confirms it's right for you).
Ro Body -- cash-pay FDA-approved GLP-1s
$39 first month · then $149/month · medication billed separately · does not bill Medicare · verified July 18, 2026
Affiliate disclosure: we may earn a commission at no cost to you. Find your path.
How The RX Index Compared the Medicare Bridge GLP-1s
We compared the current CMS Bridge program materials against the current FDA prescribing information for Wegovy, Zepbound, and Foundayo, plus the American Diabetes Association's 2026 guidance on older adults. The facts on this page trace to those primary sources; our "best fit" calls are clearly labeled as editorial judgment, based on those facts. No drug got a commission-weighted ranking.
What we actually verified ()
- CMS's current covered drugs, the $50 copay, and the 28-/30-day fill rule
- The three BMI pathways, the "measured at initiation" rule, and the 2026 exclusion for anyone whose Part D plan already paid for a GLP-1 this year
- The Bridge-vs-Part D routing rules and the diagnosis exclusions
- The prior-authorization and pharmacy process, billing route (BIN 028918 / PCN MEDDGLP1BR), and phone numbers
- The current FDA labels for all three drugs -- dosing, how each is taken, warnings, interactions, and trial results
- The older-adult representation numbers and the ADA's 2026 older-adult guidance
What we did not verify -- and won't promise: your personal eligibility, whether a drug is medically right for you, how well you'll respond, how you'll tolerate it, your pharmacy's stock, or your prescriber's willingness. Those are between you and your clinician.
We don't publish patient testimonials for this program, because it launched in July 2026 and there's no honest pool of verified results yet. When real, consented reader experiences exist, we'll add them. Who made this: The RX Index editorial team. We don't take payment from providers to rank them, and this page routes qualified Medicare readers to the public $50 program, not to a paid offer.
Frequently Asked Questions
What is the best GLP-1 on Medicare GLP-1 Bridge?
There's no single best GLP-1 on Medicare GLP-1 Bridge, because all three covered drugs cost the same $50. Zepbound had the highest average weight loss in its trial, Wegovy comes as a shot or a pill, and Foundayo is the easiest pill to take -- so the best pick depends on your body, routine, and other medications, decided with your prescriber.
Which covered drug has the most weight loss?
Zepbound (tirzepatide) showed the most average weight loss -- about 21% of body weight at 72 weeks at the 15 mg dose -- and it beat standard Wegovy injection in a direct head-to-head study (SURMOUNT-5, about 20.2% vs 13.7%). That's an average, not a promise for any one person, and the Bridge covers only Zepbound's KwikPen form.
Does the Bridge cover the Wegovy pill?
Yes. Current CMS materials include all Wegovy forms, including the daily oral tablet. It showed about 13.6% average weight loss over 64 weeks and requires a strict empty-stomach morning routine.
Does the Bridge cover Foundayo?
Yes. All FDA-approved Foundayo (orforglipron) tablet doses are covered. It's the simplest pill to take -- any time, with or without food -- with about 11% average weight loss for the approved dose over 72 weeks.
Does the Bridge cover every form of Zepbound?
No. The Bridge covers only the Zepbound KwikPen. The single-dose pen and the vials are not covered, and the program does not pay for KwikPen needles.
Is every Bridge medication really $50?
Yes. Eligible members pay a flat $50 for each covered fill (a 28- or 30-day supply), no matter which covered drug or dose, and regardless of income.
Can I get a 60- or 90-day Bridge supply?
No. Bridge fills are limited to a 28- or 30-day supply.
Does the $50 count toward my Part D out-of-pocket maximum?
No. The Bridge operates outside regular Part D, so the $50 does not count toward your deductible or your $2,100 (2026) out-of-pocket cap. Extra Help and manufacturer coupons can't lower it, either.
Can I pay cash and get reimbursed by the Bridge?
No. The Bridge does not accept paper claims or direct member reimbursement; the pharmacy bills it electronically.
Do I need a Part D denial before using the Bridge?
No. CMS does not require a Part D denial first. Your prescriber can direct the pharmacy to send an eligible weight-management claim straight to the Bridge.
Who qualifies for the Medicare GLP-1 Bridge?
You must be at least 18, enrolled in an eligible Part D or Medicare Advantage drug plan, using the drug for weight management with diet and exercise, and meet one of CMS's BMI pathways: a BMI of 35 or higher at the time you started a GLP-1; a BMI of 30 or higher with HFpEF, chronic kidney disease (stage 3a+), or uncontrolled high blood pressure; or a BMI of 27 or higher with prediabetes, peripheral artery disease, or a prior heart attack or stroke. You're not eligible in 2026 if Part D already paid for a GLP-1 for you this year, and the excluded-diagnosis rules also apply.
Can I use the Bridge if I have type 2 diabetes or sleep apnea?
Generally no. If you have type 2 diabetes, moderate-to-severe sleep apnea, or noncirrhotic MASH with moderate-to-advanced scarring, your GLP-1 goes through the regular Part D process instead. Established heart disease alone is not an automatic exclusion -- a prescription to reduce heart events uses Part D, but a genuine weight-management prescription may still use the Bridge if you meet every other requirement.
Do I need a new prior authorization when my dose changes or I switch drugs?
Not for a dose change on the same covered drug after your first approval. You do need a new prior authorization if you switch to a different covered drug. Any switch or dose change should be directed by your prescriber.
Can my doctor prescribe even if they're not enrolled in Medicare?
Yes. CMS says the prescriber doesn't have to be enrolled in Medicare -- but they can't be on the CMS Preclusion List. You cannot submit the prior authorization yourself; a prescriber must.
Are compounded GLP-1s part of the Bridge?
No. The Bridge covers only named, FDA-approved products. Compounded semaglutide and tirzepatide are not FDA-approved and are not part of the program.
What happens after December 31, 2027?
The Bridge is scheduled to end that day. Its successor program wasn't launched for 2027, so there's no guaranteed path afterward unless there's new federal action, which CMS hasn't announced. Watch CMS for updates.
Still deciding? Get a personalized match in about 60 seconds.
The RX Index's Find My GLP-1 Path tool weighs your insurance situation, your state, whether you'd rather take a pill or a shot, and your budget -- and points you to the path that fits. It doesn't diagnose your eligibility or replace your clinician; it just helps you take the next step with confidence.
Take the free 60-second quiz →Free · No signup · No diagnosis
Sources we checked (primary and authoritative)
- Centers for Medicare & Medicaid Services -- Medicare GLP-1 Bridge: overview, Information for Providers, Information for Pharmacies, Information for Part D Plans, and the prior-authorization form and payer sheet (cms.gov)
- Medicare.gov -- Weight-loss drugs coverage and the Medicare GLP-1 Bridge fact sheet
- U.S. Food & Drug Administration / DailyMed -- current prescribing information for Wegovy (semaglutide), Zepbound (tirzepatide), and Foundayo (orforglipron)
- SURMOUNT-1, SURMOUNT-4, SURMOUNT-5, STEP 1, STEP UP, OASIS 4, and ATTAIN-1 trial results, via The New England Journal of Medicine, The Lancet Diabetes & Endocrinology, and manufacturer disclosures (Eli Lilly, Novo Nordisk)
- American Diabetes Association -- Standards of Care in Diabetes 2026, Section 13: Older Adults (diabetesjournals.org)
- KFF -- analysis of Medicare GLP-1 Bridge eligibility (kff.org)
This article is educational and is not medical advice. Medicare rules, prices, and drug labels change -- always confirm current details with CMS, your Part D plan, and your prescriber before acting.